RMC-4998

Overview

RMC-4998 is an orally active inhibitor targeting the active or GTP-bound state of the KRAS G12C mutant. RMC-4998 can form a ternary complex with intracellular CYPA and the activated KRAS G12C mutant, with an IC 50 value of 28 nM. RMC-4998 can inhibit ERK signaling in KRAS G12C mutant cancer cells and induce apoptosis . RMC-4998 can be used for tumor research.

Application

Products | Products > Signaling Pathways > GPCR/G Protein | Products > Signaling Pathways > MAPK/ERK Pathway | Products > Signaling Pathways > PI3K/Akt/mTOR | Products > Signaling Pathways > Stem Cell/Wnt | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Stem Cells | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > mTOR | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > Ras | Products > Signaling Pathways > PI3K | Products > Signaling Pathways > ERK

Product Information

• Catalog No.: HY-156671
• CAS No.: 2642037-07-6
• Molecular Formula: C57H74N8O7
• Molecular Weight: 983.25
• Purity: 99.31%
• Storage: 4°C, stored under nitrogen * In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
• Solubility: ≥ 2.5 mg/mL (2.54 mM); Clear solution
• Availability: In-stock

Source

Original product source